CTRP3 is a novel biomarker for diabetic retinopathy and inhibits HGHL-induced VCAM-1 expression in an AMPK-dependent manner.

MLA

Zheyi Yan, et al. “CTRP3 Is a Novel Biomarker for Diabetic Retinopathy and Inhibits HGHL-Induced VCAM-1 Expression in an AMPK-Dependent Manner.” PLoS ONE, vol. 12, no. 6, Jan. 2017, p. e0178253. EBSCOhost, https://doi.org/10.1371/journal.pone.0178253.

APA

Zheyi Yan, Jianli Zhao, Lu Gan, Yanqing Zhang, Rui Guo, Xiaoming Cao, Wayne Bond Lau, Xin Ma, & Yajing Wang. (2017). CTRP3 is a novel biomarker for diabetic retinopathy and inhibits HGHL-induced VCAM-1 expression in an AMPK-dependent manner. PLoS ONE, 12(6), e0178253. https://doi.org/10.1371/journal.pone.0178253

Chicago

Zheyi Yan, Jianli Zhao, Lu Gan, Yanqing Zhang, Rui Guo, Xiaoming Cao, Wayne Bond Lau, Xin Ma, and Yajing Wang. 2017. “CTRP3 Is a Novel Biomarker for Diabetic Retinopathy and Inhibits HGHL-Induced VCAM-1 Expression in an AMPK-Dependent Manner.” PLoS ONE 12 (6): e0178253. doi:10.1371/journal.pone.0178253.